[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Astrazeneca Plc (AZN)

Astrazeneca Plc (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

AstraZeneca's Monday Morning Call Will Reveal Whether Anyone Still Believes the Margin Math

AstraZeneca (AZN) reports second-quarter 2026 earnings before the market opens on Sunday, July 27, with analysts expecting $2.50 per share on continued momentum from its oncology and rare disease franchises. The pharmaceutical giant faces a critical test: can it sustain double-digit growth while navigating patent cliffs and an increasingly competitive biosimilar landscape? With the stock down sharply from recent highs and technical indicators flashing warning signs, this report will either validate the growth story or deepen concerns about valuation and execution.

AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in oncology, cardiovascular, renal, metabolism, and...

Fundamentals

See More
  • Market Capitalization, $K 260,971,280
  • Shares Outstanding, K 1,550,908
  • Annual Sales, $ 58,739 M
  • Annual Income, $ 10,225 M
  • EBIT $ 14,315 M
  • EBITDA $ 20,048 M
  • 60-Month Beta 0.24
  • Price/Sales 4.48
  • Price/Cash Flow 13.13
  • Price/Book 5.56

Options Overview Details

View History
  • Implied Volatility 31.21% (-0.82%)
  • Historical Volatility 37.36%
  • IV Percentile 91%
  • IV Rank 79.51%
  • IV High 34.22% on 02/05/26
  • IV Low 19.54% on 08/14/25
  • Expected Move (DTE 27) 9.73 (5.75%)
  • Put/Call Vol Ratio 0.49
  • Today's Volume 1,533
  • Volume Avg (30-Day) 1,983
  • Put/Call OI Ratio 0.89
  • Today's Open Interest 65,010
  • Open Int (30-Day) 70,351
  • Expected Range 159.53 to 178.99

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $2.50
  • Number of Estimates 2
  • High Estimate $2.50
  • Low Estimate $2.49
  • Prior Year $2.18
  • Growth Rate Est. (year over year) +14.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
164.06 +3.17%
on 07/20/26
196.41 -13.82%
on 07/02/26
-13.76 (-7.52%)
since 06/24/26
3-Month
164.06 +3.17%
on 07/20/26
196.41 -13.82%
on 07/02/26
-20.49 (-10.80%)
since 04/24/26
52-Week
142.98 +18.38%
on 07/28/25
212.71 -20.43%
on 02/18/26
+21.90 (+14.86%)
since 07/24/25

Most Recent Stories

More News
AstraZeneca's Monday Morning Call Will Reveal Whether Anyone Still Believes the Margin Math

Barchart Research What to Expect from AZN Earnings AZN Generated July 24, 2026 Current Price $169.26 EPS Estimate $$2.50 Consensus Rating Strong Buy Average Move 2.07% AstraZeneca's Monday Morning Call...

AZN : 169.26 (+0.59%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

NEW YORK , July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NYSE: AZN).  Such investors are advised...

AZN : 169.26 (+0.59%)
AZN Investors Have Opportunity to Join AstraZeneca PLC Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AstraZeneca PLC (“AstraZeneca” or “the Company”)...

AZN : 169.26 (+0.59%)
3 Gold-Rated Schwab ETFs to Buy

When it comes to major ETF providers, Schwab might not be first to mind, but they offer up several solid, low-cost products that investors can build around.

NVDA : 206.84 (-0.92%)
GOOG : 319.09 (+0.24%)
GOOGL : 319.74 (+0.65%)
SCHO : 24.06 (+0.08%)
AAPL : 333.02 (+3.53%)
AZN : 169.26 (+0.59%)
SCHX : 29.12 (+0.10%)
SCHF : 27.04 (-0.15%)
HSBC : 103.40 (+1.62%)
NSRGY : 98.5200 (+2.00%)
AstraZeneca (AZN) Securities Investigation Notice - Levi & Korsinsky

AstraZeneca (AZN) shares fell roughly 8% as the market opened on July 9, 2026. Investors who held AZN and lost money are examining whether the losses tied to this collapse may be recoverable.

AZN : 169.26 (+0.59%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

NEW YORK , July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NYSE: AZN).  Such investors are advised...

AZN : 169.26 (+0.59%)
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions

Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.

AZN : 169.26 (+0.59%)
ALNY : 271.77 (+1.13%)
IONS : 56.55 (+1.22%)
BBIO : 84.02 (+1.31%)
PFE : 24.54 (-0.16%)
AZN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into AstraZeneca (AZN)

AstraZeneca (AZN) shares fell approximately 8.4% in early trading on July 9, 2026, following a Phase III trial failure. SueWallSt notifies investors of a pending investigation into potential claims on...

AZN : 169.26 (+0.59%)
AstraZeneca Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into AstraZeneca (AZN)

AstraZeneca (AZN) announced its key CARDIO-TTRansform Phase III trial missed its primary endpoint. SueWallSt notifies investors of a pending investigation into potential securities claims on behalf of...

AZN : 169.26 (+0.59%)
Tempus AI Stock Faces a Make-or-Break Moment After Its Recent Pullback

Tempus AI's stock has hit a rough patch, but fundamentals remain solid. What does it mean for investors?

ARKG : 37.81 (-2.60%)
AZN : 169.26 (+0.59%)
MRK : 131.07 (+0.45%)
GILD : 129.31 (-1.18%)
TEM : 42.69 (-7.22%)
GSK : 51.35 (+1.20%)
ARKK : 71.89 (-2.63%)
BMY : 62.09 (+0.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition...

See More

Key Turning Points

3rd Resistance Point 172.17
2nd Resistance Point 171.21
1st Resistance Point 170.24
Last Price 169.26
1st Support Level 168.31
2nd Support Level 167.35
3rd Support Level 166.38

See More

52-Week High 212.71
Fibonacci 61.8% 186.07
Fibonacci 50% 177.85
Fibonacci 38.2% 169.62
Last Price 169.26
52-Week Low 142.98

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.